Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 27:2018:8631237.
doi: 10.1155/2018/8631237. eCollection 2018.

Periosteal Osteosarcoma: A Single-Institutional Study of Factors Related to Oncologic Outcomes

Chung Ming Chan  1 , Adam D Lindsay  2 , Andre R V Spiguel  1 , C Parker Gibbs Jr  1 , Mark T Scarborough  1
Affiliations

Periosteal Osteosarcoma: A Single-Institutional Study of Factors Related to Oncologic Outcomes

Chung Ming Chan et al. Sarcoma. .

Abstract

Background: Periosteal osteosarcoma is a rare surface-based variant with a lower propensity to metastasis and better prognosis than conventional osteosarcoma. The literature supporting survival benefit with adjuvant chemotherapy is lacking. Our institutional practice is for chemotherapy to be offered to patients with high-grade disease.

Methods: We conducted a retrospective cohort study of patients managed for periosteal osteosarcoma from 1970 to 2015 analyzing the survival outcomes and assessing for any relationship of survival to patient- or treatment-related factors. 18 patients were included. The study population presented at a mean of 20.8 years and was followed for a mean of 10.7 years. Factors assessed for an association with survival included age, size of tumor, use of chemotherapy, presence of medullary involvement, presence of high-grade disease, local recurrence, and site of disease. Kaplan-Meier survival analysis and Cox proportional hazard regression were performed to calculate the survival rates and to assess for the effect of any factor on survival.

Results: 10-year overall survival rate was 77.1%, and 10-year event-free survival rate was 66.4%. No factor was found to have an association with overall or event-free survival.

Conclusion: These findings add to the available evidence which has failed to find any survival benefit from chemotherapy; patients with this rare disease and their families should be counselled regarding the unclear role of chemotherapy in this rare subtype of osteosarcoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of primary tumors in study population by age and location.
Figure 2
Figure 2
Kaplan–Meier curve of overall survival of study population.
Figure 3
Figure 3
Kaplan–Meier curve of event-free survival of study population.
Figure 4
Figure 4
Kaplan–Meier curves comparing overall survival (a) and event-free survival (b) of patients who did and did not receive chemotherapy.
See this image and copyright information in PMC

References

    1. Fletcher C. D. M., Bridge J. A., Hogendoorn P. C. W., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2013.
    1. Rose P. S., Dickey I. D., Wenger D. E., Unni K. K., Sim F. H. Periosteal osteosarcoma: long-term outcome and risk of late recurrence. Clinical Orthopaedics and Related Research. 2006;453:314–317. doi: 10.1097/01.blo.0000229341.18974.95. - DOI - PubMed
    1. Bertoni F., Boriani S., Laus M., Campanacci M. Periosteal chondrosarcoma and periosteal osteosarcoma: two distinct entities. Journal of Bone and Joint Surgery. 1982;64(3):370–376. doi: 10.1302/0301-620x.64b3.7096408. - DOI - PubMed
    1. Campanacci M., Giunti A. Periosteal osteosarcoma. Review of 41 cases, 22 with long-term follow-up. Italian Journal of Orthopaedics and Traumatology. 1976;2(1):23–35. - PubMed
    1. Ritts G. D., Pritchard D. J., Unni K. K., Beabout J. W., Eckardt J. J. Periosteal osteosarcoma. Clinical Orthopaedics and Related Research. 1987;219:299–307. doi: 10.1097/00003086-198706000-00041. - DOI - PubMed

LinkOut - more resources